$44.5 Million is the total value of OUP Management Co., LLC's 12 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $19,006,369 | +4.5% | 2,937,615 | 0.0% | 42.74% | +37.8% | |
| AVTE | Aerovate Therapeutics Inc. | $8,193,050 | -20.9% | 603,762 | 0.0% | 18.42% | +4.3% | |
| CYT | Cyteir Therapeutics, Inc. | $6,985,184 | +9.2% | 2,459,572 | 0.0% | 15.71% | +44.0% | |
| PMVP | PMV Pharmaceuticals, Inc. | $6,073,884 | -1.9% | 989,232 | 0.0% | 13.66% | +29.3% | |
| GRPH | Graphite Bio | $1,007,644 | -4.6% | 406,308 | 0.0% | 2.27% | +25.7% | |
| SELB | Selecta Biosciences, Inc. | $914,296 | -5.4% | 862,543 | 0.0% | 2.06% | +24.8% | |
| VOR | Vor Biopharma Inc. | $794,394 | -31.4% | 374,714 | 0.0% | 1.79% | -9.5% | |
| eFFECTOR Therapeutics, Inc. | $615,316 | -27.7% | 1,025,697 | 0.0% | 1.38% | -4.7% | ||
| DTIL | Precision BioSciences, Inc. | $383,592 | -35.1% | 1,123,913 | 0.0% | 0.86% | -14.4% | |
| SPRO | Spero Therapeutics, Inc. | $301,375 | -16.6% | 249,070 | 0.0% | 0.68% | +10.1% | |
| IKNA | New | Ikena Oncology, Inc. | $116,187 | – | 26,833 | +100.0% | 0.26% | – |
| FIXX | Homology Medicines, Inc. | $74,880 | +32.2% | 64,000 | 0.0% | 0.17% | +73.2% | |
| Exit | DICE Therapeutics Inc. | $0 | – | -268,346 | -100.0% | -21.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
| Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
| PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
| Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
| Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
| Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
| Graphite Bio | 8 | Q3 2023 | 2.3% |
| eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
| Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
| Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-24 |
| 13F-HR | 2023-02-02 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-19 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.